{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:44:17Z","timestamp":1791531857669,"version":"4.3.4"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Wockhardt Limited, Mumbai, India"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>WCK 5222 is a novel \u03b2-lactam\u2013\u03b2-lactam-enhancer combination of cefepime (FEP) and zidebactam (ZID). ZID is a novel \u03b2-lactam enhancer with a dual action of binding to Gram-negative penicillin-binding protein 2 (PBP2) and \u03b2-lactamase inhibition.<\/jats:p>","DOI":"10.1128\/aac.01484-18","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T06:15:50Z","timestamp":1545286550000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":38,"title":["Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment"],"prefix":"10.1128","volume":"63","author":[{"given":"Richard A.","family":"Preston","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Research Unit, Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA"},{"name":"University of Miami Clinical and Translational Science Institute (CTSI), Miami, Florida, USA"},{"name":"Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA"},{"name":"Jackson Memorial Hospital, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigor","family":"Mamikonyan","sequence":"additional","affiliation":[{"name":"Clinartis LLC, Hollywood, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"DeGraff","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Research Unit, Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chiou","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Research Unit, Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Kemper","sequence":"additional","affiliation":[{"name":"Pharma Navigators, LLC, Lawrenceville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Xu","sequence":"additional","affiliation":[{"name":"Keystone Bioanalytical, Inc., North Wales, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mushtaque","family":"Mastim","sequence":"additional","affiliation":[{"name":"Wockhardt Limited, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Yeole","sequence":"additional","affiliation":[{"name":"Wockhardt Limited, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Chavan","sequence":"additional","affiliation":[{"name":"Wockhardt Limited, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anasuya","family":"Patel","sequence":"additional","affiliation":[{"name":"Wockhardt Limited, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. David","family":"Friedland","sequence":"additional","affiliation":[{"name":"Wockhardt's Morton Grove Pharmaceutical, Inc., Morton Grove, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashima","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Wockhardt Limited, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00037-09"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02529-16"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw593"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01238-17"},{"key":"e_1_3_2_6_2","volume-title":"WCK 5222 [cefepime-zidebactam, FEP-ZID]: mechanistic basis behind novel \u03b2-lactam\u2013\u03b2-lactam enhancer combination against metallo-\u03b2-lactamase (MBL)-producing E. coli (EC), K. pneumoniae (KP), P. aeruginosa (PA) and its impact on therapeutically relevant bactericidal exposures assessed through in vitro pharmacodynamic modelling (IVPM) and mouse lung eradication studies","author":"Moya B","year":"2016","unstructured":"Moya B, Barcelo I, Udaykar A, Bhagwat S, Patel M, Bou G, Oliver A. 2016. WCK 5222 [cefepime-zidebactam, FEP-ZID]: mechanistic basis behind novel \u03b2-lactam\u2013\u03b2-lactam enhancer combination against metallo-\u03b2-lactamase (MBL)-producing E. coli (EC), K. pneumoniae (KP), P. aeruginosa (PA) and its impact on therapeutically relevant bactericidal exposures assessed through in vitro pharmacodynamic modelling (IVPM) and mouse lung eradication studies, abstr 1982. IDWeek 2016, 26 to 30 October 2016, New Orleans, LA."},{"key":"e_1_3_2_7_2","unstructured":"Hospira. 2012. Maxipime (cefepime hydrochloride USP) for injection for intravenous or intramuscular use. Hospira Inc. Lake Forest IL. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/050679s036lbl.pdf."},{"key":"e_1_3_2_8_2","volume-title":"WCK 5107 (zidebactam, ZID): a pan Gram-negative \u03b2-lactam enhancer augmenting \u03b2-lactam pharmacodynamics in wild type and carbapenemase producers (CP)","author":"Palwe S","year":"2016","unstructured":"Palwe S, Joshi PR, Khande HN, Biniwale SS, Bhagwat SS, Patel MV. 2016. WCK 5107 (zidebactam, ZID): a pan Gram-negative \u03b2-lactam enhancer augmenting \u03b2-lactam pharmacodynamics in wild type and carbapenemase producers (CP), poster 438. ASM Microbe, 16 to 20 June 2016, Boston, MA."},{"key":"e_1_3_2_9_2","volume-title":"WCK 5222 [cefepime (FEP)-WCK 5107 (zidebactam, ZID)]: activity against ESBL, class C, and KPC-expressing enterics and Pseudomonas (PA) expressing AmpC (PS AmpC) or OXA \u03b2-lactamases (PS OXA)","author":"Khande HN","year":"2016","unstructured":"Khande HN, Joshi PR, Palwe S, Bhagwat SS, Patel MV. 2016. WCK 5222 [cefepime (FEP)-WCK 5107 (zidebactam, ZID)]: activity against ESBL, class C, and KPC-expressing enterics and Pseudomonas (PA) expressing AmpC (PS AmpC) or OXA \u03b2-lactamases (PS OXA). ASM Microbe, 16 to 20 June 2016, Boston, MA."},{"key":"e_1_3_2_10_2","unstructured":"Wockhardt. 2016. Investigator\u2019s brochure cefepime-zidebactam: a novel \u03b2-lactam\u2013\u03b2-lactam enhancer based combination for Gram negative infections. Wockhardt Mumbai India."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00072-17"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx050"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.6.6.805"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.149"},{"key":"e_1_3_2_15_2","first-page":"63","article-title":"Pharmacokinetic properties of beta-lactamase inhibitors","volume":"37","author":"de la Pena A","year":"1999","unstructured":"de la Pena A, Derendorf H. 1999. Pharmacokinetic properties of beta-lactamase inhibitors. Int J Clin Pharmacol Ther 37:63\u201375.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_3_2_16_2","first-page":"482","article-title":"Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment","volume":"34","author":"Derendorf H","year":"1996","unstructured":"Derendorf H, Costa TD. 1996. Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment. Int J Clin Pharmacol Ther 34:482\u2013488.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_3_2_17_2","volume-title":"Guideline for good clinical practice E6(R1)","author":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for Human Use","year":"1996","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for Human Use. 1996. ICH harmonized tripartite guideline. Guideline for good clinical practice E6(R1). International Council for Harmonisation, Geneva, Switzerland. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf."},{"key":"e_1_3_2_18_2","volume-title":"Guidance for industry. Pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing and labeling","author":"Center for Drug Evaluation and Research (CDER)","year":"2010","unstructured":"Center for Drug Evaluation and Research (CDER). 2010. Guidance for industry. Pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing and labeling. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Silver Spring, MD. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm204959.pdf."},{"key":"e_1_3_2_19_2","unstructured":"Food and Drug Administration. 2010. Summary minutes of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology March 17 2010. \nhttps:\/\/wayback.archive-it.org\/7993\/20170113113150\/http:\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology\/UCM210807.pdf."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.190"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.182"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01484-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01484-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:20:51Z","timestamp":1645460451000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01484-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1128\/AAC.01484-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.01484-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"2018-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01484-18"}}